| scholarly article | Q13442814 |
| P50 | author | Stefan Wiemann | Q38155058 |
| Zita Soons | Q54153124 | ||
| Kirti Shukla | Q57076892 | ||
| Aleksandra Balwierz | Q58329967 | ||
| P2093 | author name string | Rainer König | |
| Ozgür Sahin | |||
| Aoife Ward | |||
| P2860 | cites work | Identification of mammalian microRNA host genes and transcription units | Q24562298 |
| miRBase: integrating microRNA annotation and deep-sequencing data | Q24615914 | ||
| MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1 | Q24648241 | ||
| The impact of microRNAs on protein output | Q24653549 | ||
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer | Q26862550 | ||
| The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen | Q27766417 | ||
| Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists | Q28131785 | ||
| Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells | Q28216467 | ||
| Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study | Q28729855 | ||
| miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors | Q28742532 | ||
| The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups | Q29614700 | ||
| Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance | Q33396832 | ||
| Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours | Q34150301 | ||
| miRWalk--database: prediction of possible miRNA binding sites by "walking" the genes of three genomes | Q34186822 | ||
| Mechanisms of tamoxifen resistance | Q34378877 | ||
| Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. | Q34506613 | ||
| High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. | Q34549892 | ||
| Analysis of apoptosis by propidium iodide staining and flow cytometry | Q34615421 | ||
| Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer | Q34635861 | ||
| Modelling breast cancer: one size does not fit all. | Q34667643 | ||
| Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer | Q34816422 | ||
| The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer | Q35191588 | ||
| Combinatorial RNAi for quantitative protein network analysis | Q35745179 | ||
| Tamoxifen-stimulated growth of breast cancer due to p21 loss | Q36423493 | ||
| Mechanisms of Endocrine Resistance in Breast Cancer | Q36851417 | ||
| miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels | Q37068662 | ||
| MicroRNA and drug resistance | Q37751868 | ||
| Endocrine pharmacology of antiestrogens as antitumor agents | Q38038012 | ||
| Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer | Q39363790 | ||
| Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells | Q39618112 | ||
| miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer | Q39698184 | ||
| Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region | Q39733975 | ||
| Apoptotic effects of signal transduction inhibitors on human tumor cells with different PTEN expression | Q40072282 | ||
| Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer | Q40544950 | ||
| Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens | Q40614262 | ||
| Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites | Q43685275 | ||
| Tamoxifen long-term treatment in vitro alters the apoptotic response of MCF-7 breast cancer cells | Q45115291 | ||
| In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. | Q51542616 | ||
| The dark side of a success story: microRNAs of the C19MC cluster in human tumours. | Q54526480 | ||
| microRNA-Associated Progression Pathways and Potential Therapeutic Targets Identified by Integrated mRNA and microRNA Expression Profiling in Breast Cancer | Q58211596 | ||
| Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer | Q67710267 | ||
| Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells | Q77557300 | ||
| P433 | issue | 4 | |
| P921 | main subject | breast cancer | Q128581 |
| microRNA | Q310899 | ||
| tamoxifen | Q412178 | ||
| P304 | page(s) | 368-379 | |
| P577 | publication date | 2014-06-02 | |
| P1433 | published in | Journal of Pathology | Q400296 |
| P1476 | title | MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer | |
| P478 | volume | 233 |
| Q64109398 | A perspective on the diagnostics, prognostics, and therapeutics of microRNAs of triple-negative breast cancer |
| Q98164950 | Analysis of conserved miRNAs in cynomolgus macaque genome using small RNA sequencing and homology searching |
| Q36502389 | Analysis of factors affecting endocrine therapy resistance in breast cancer |
| Q49163340 | Bioinformatics-based identification of miR-542-5p as a predictive biomarker in breast cancer therapy |
| Q47730656 | Breast cancer stem-like cells are sensitized to tamoxifen induction of self-renewal inhibition with enforced Let-7c dependent on Wnt blocking. |
| Q58601661 | Chromosome 19 miRNA cluster and CEBPB expression specifically mark and potentially drive triple negative breast cancers |
| Q35930811 | Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas. |
| Q35137273 | Critical analysis of the potential for microRNA biomarkers in breast cancer management. |
| Q52714385 | Cyclin D1-mediated microRNA expression signature predicts breast cancer outcome. |
| Q28069370 | Decoding the usefulness of non-coding RNAs as breast cancer markers |
| Q64974925 | Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy. |
| Q40245310 | Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: An update |
| Q28066481 | Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer |
| Q35709636 | Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. |
| Q38708204 | Human and primate-specific microRNAs in cancer: Evolution, and significance in comparison with more distantly-related research models: The great potential of evolutionary young microRNA in cancer research. |
| Q36808390 | MIR517C inhibits autophagy and the epithelial-to-mesenchymal (-like) transition phenotype in human glioblastoma through KPNA2-dependent disruption of TP53 nuclear translocation |
| Q27011221 | Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA |
| Q37641578 | MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy |
| Q48837549 | MiR-519a functions as a tumor suppressor in glioma by targeting the oncogenic STAT3 pathway |
| Q54944098 | MicroRNA and Breast Cancer: Understanding Pathogenesis, Improving Management. |
| Q41593018 | MicroRNA profiles involved in trifluridine resistance |
| Q35128098 | MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer |
| Q38904555 | MicroRNA-30c-2-3p negatively regulates NF-κB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer |
| Q36320426 | MicroRNA-519a promotes proliferation and inhibits apoptosis of hepatocellular carcinoma cells by targeting FOXF2. |
| Q36571466 | MicroRNA-519a promotes tumor growth by targeting PTEN/PI3K/AKT signaling in hepatocellular carcinoma |
| Q41169679 | MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells |
| Q60958994 | Non-Coding RNAs in Breast Cancer: Intracellular and Intercellular Communication |
| Q92917073 | Non-coding RNAs as Mediators of Tamoxifen Resistance in Breast Cancers |
| Q36417380 | Parsing interindividual drug variability: an emerging role for systems pharmacology |
| Q90401748 | Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer |
| Q26783076 | Roles for miRNAs in endocrine resistance in breast cancer |
| Q26739969 | Tamoxifen Resistance: Emerging Molecular Targets |
| Q36992190 | Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review). |
| Q26782449 | The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients |
| Q98771207 | The Similar Effects of miR-512-3p and miR-519a-2-5p on the Promotion of Hepatocellular Carcinoma: Different Tunes Sung With Equal Skill |
| Q38381678 | The novel role of miRNAs for tamoxifen resistance in human breast cancer |
| Q26787004 | The reversal of antineoplastic drug resistance in cancer cells by β-elemene |
| Q35932634 | miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A. |
| Q37236236 | miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer. |
| Q37316805 | miRNA clusters as therapeutic targets for hormone-resistant breast cancer |
| Q35912303 | miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets. |
| Q57106025 | microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy |
Search more.